Cross-Border Impact Ventures

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

OXcan raises £9m Series A led by We Venture Capital and Cross-Border Impact Ventures to revolutionise early lung cancer detection

9 Jan 2025

OXcan raises £9m Series A led by We Venture Capital and Cross-Border Impact Ventures to revolutionise early lung cancer detection

OXcan develops blood-based liquid biopsy tests using proteomics and AI to detect lung cancer at earlier stages, enabling minimally invasive screening designed to improve outcomes and reduce pressure on healthcare systems.

Cross-Border Impact Ventures

- Life Sciences
crossborder.ventures
Update Information

More venture news

Combat Medical
12 Mar 2026
Combat Medical raises a £2.6m Series A led by T&J Meyer Family Foundation for hard-to-treat bladder cancer
Series AHealth
Outpost
10 Mar 2026
Outpost unlocks £13m Series A led by Ribbit for cross-border payments and tax compliance infrastructure
Series AFintech
4 Mar 2026
Shellworks raises £11m Series A led by Alter Equity for biodegradable packaging made from microbial fermentation
Series ASupply Chain

Cross-Border Impact Ventures

Investment Portfolio

OXcan raises £9m Series A led by We Venture Capital and Cross-Border Impact Ventures to revolutionise early lung cancer detection

More venture news

Combat Medical raises a £2.6m Series A led by T&J Meyer Family Foundation for hard-to-treat bladder cancer

Outpost unlocks £13m Series A led by Ribbit for cross-border payments and tax compliance infrastructure

Shellworks raises £11m Series A led by Alter Equity for biodegradable packaging made from microbial fermentation